Inhibition of monosodium urate monohydrate-mediated hemolysis by vitamin E

Gout and Diet: A Comprehensive Review of Mechanisms and Management

Gout is well known as an inflammatory rheumatic disease presenting with arthritis and abnormal metabolism of uric acid. The recognition of diet-induced systemic metabolic pathways have provided new mechanistic insights and potential interventions on gout progression. However, the dietary recommendations for gouty patients generally focus on food categories, with few simultaneous considerations of nutritional factors and systemic metabolism. It is worthwhile to comprehensively review the mechanistic findings and potential interventions of diet-related nutrients against the development of gout, including purine metabolism, urate deposition, and gouty inflammation. Although piecemeal modifications of various nutrients often provide incomplete dietary recommendations, understanding the role of nutritional factors in gouty development can help patients choose their healthy diet based on personal preference and disease course. The combination of dietary management and medication may potentially achieve enhanced treatment effects, especially for severe patients. Therefore, the role of dietary and nutritional factors in the development of gout is systematically reviewed to propose dietary modification strategies for gout management by: (1) reducing nutritional risk factors against metabolic syndrome; (2) supplementing with beneficial nutrients to affect uric acid metabolism and gouty inflammation; and (3) considering nutritional modification combined with medication supplementation to decrease the frequency of gout flares.

Stimuli-responsive polypropylene for the sustained delivery of TPGS and interaction with erythrocytes

Hemocompatibility and oxidative stress are significant for blood-contacting devices. In this study, N-isopropylacrylamide (NIPAAm) and N-(3-aminopropyl)methacrylamide hydrochloride (APMA) were cografted on polypropylene (PP) membrane using ultraviolet grafting to load antioxidative d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) and control the release of TPGS. The immobilization of NIPAAm and APMA onto PP membrane was confirmed by attenuated total reflectance Fourier-transform infrared spectroscopy and X-ray photoelectron spectroscopy. Combined with data from platelet adhesion, red blood cell (RBC) attachment, and hemolysis rate, the hemocompatibility of PP was significantly improved. An in-depth characterization using hemolysis rate test, scanning electron microscopy, atomic force microscopy, and confocal laser scanning microscopy was conducted to confirm that the mechanism of the release of TPGS interacted with RBCs was different at different stages. The release of TPGS from the loading PP membranes affected hemolysis at different stages. At the early stage of release, TPGS maintained the tiny (nanometer-sized) tubers on the membrane surface and enhanced the membrane permeabilization by generating nanosized pores on the cell membranes. Afterward, the incorporated TPGS slowed the lipid peroxidation of erythrocytes and filled in the lipid bilayer of erythrocyte to prevent hemolysis. Thus, the approach implemented to graft NIPAAm and APMA and load TPGS was suitable to develop medical device with excellent hemocompatibility and antioxidative property.